semaglutide and epilepsy Linked to Lower Risk in Type 2 Diabetes GLP-1 diabetes drugs linked to

Dulaglutide is an option when eGFR is above 15 mL/min/1.73 m, but adjustments may be necessary for severe impairment

Baseline epifluorescence and transmitted phase contrast images were acquired using a 20X magnification 0.75 NA objective from 4 positions per well using the imaging system in Section 2.8

[82] The trial reported cumulative occurrence of major adverse cardiovascular events, a primary end-point event of the trial, for 569 of the 8803 patients in the semaglutide group, which were 6.5% of the participants, and for 701 of the 8801 patients in the placebo group, which were 8% of the participants, showing relative 18.8% less major adverse cardiovascular events, such as death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, occurring for participants who had received semaglutide in the trial relative to those who had received placebo over the course of around 48 months, or 34.213.7 months, which was the mean (SD) total duration of the participants in either group's exposure to the placebo or semaglutide during the trial

AI models integrating these variables could forecast expected weight loss and side effect risk, guiding treatment selection and dose titration